The Vanguard Group files 13G/A showing 13.49% stake in WST
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary
West Pharmaceutical Services (WST): Schedule 13G/A filed by The Vanguard Group
The Vanguard Group reported beneficial ownership of 9,704,948 shares of WST common stock, representing 13.49% of the class as of 09/30/2025. Vanguard reported 0 shares with sole voting power and 422,261 with shared voting power. It reported 9,018,715 shares with sole dispositive power and 686,233 with shared dispositive power.
Vanguard states the securities are held in the ordinary course and not to influence control. Its clients have the right to receive dividends or sale proceeds, and no single client’s interest exceeds 5%.
Positive
- None.
Negative
- None.
FAQ
What stake in WST did The Vanguard Group report?
The Vanguard Group reported beneficial ownership of 13.49% of West Pharmaceutical Services common stock.
What voting power did The Vanguard Group report for WST?
Vanguard reported 0 shares with sole voting power and 422,261 shares with shared voting power.
What dispositive power did The Vanguard Group report for WST?
Vanguard reported 9,018,715 shares with sole dispositive power and 686,233 shares with shared dispositive power.
Is The Vanguard Group filing passive for WST?
Yes. Vanguard certified the holdings were acquired and are held in the ordinary course and not to change or influence control.
Do any Vanguard clients hold more than 5% of WST?
No. Vanguard states no one other person's interest exceeds 5%.
What is the event date for this ownership report?
The date of the event is 09/30/2025.